Shortening the Drug Discovery timeline through advanced machine learning techniques
Dr. David Wolf, President and Chief Medical Officer for Spektron Systems will be speaking on a panel about AI in Healthcare on Tuesday, February 12th, 2019 at 7:00pm. The panel presentation is hosted by IMPACTIVE BioConsult and will be attended by investors looking to learn more about the subject. Attendance is by invite-only. For more information contact andrea@impactivebioconsult.com. Read more.
As an extension of our relationship with the National Center for Toxicological Research, Spektron Systems has developed a platform for AI-assisted drug design. The goal of the platform is to shortens discovery timelines in developing preclinical candidates from 4.5+ years to approximately 1 year. We target a $10M cost of discovery opposed to costs that can reach $100M+. Our approach shows a strong potential to disruptively improve pharmaceutical pipeline success.
Spektron Systems has developed a platform, Q-MAP™, for designing new molecules which we will carry through pre-clinical testing. Q-MAP™ combines modern methods of machine learning and computational chemistry to build models using available training data on multiple endpoints. We have developed predictive models for virtual screening of molecules on a variety of endpoints toxicity, efficacy, and side-effects. This ability to screen molecules in-silico is available for Spektron’s drug discovery pipeline as well as for our partners.
In the course of developing our platform, we necessarily selected a target therapeutic area. Our initial datasets were built in the area of psychiatric drugs targeting relief for symptoms of schizophrenia, depression, and bipolar disorder. In the first iteration of the platform, we developed over 15,000 novel molecules and processed them through our in-silico pipeline arriving at ~60 Q-MAP™ Optimized Leads for an atypical antipsychotic with reduced risk and tolerability issues. As we continue development on the platform, a second iteration will build confidence in the designed molecules we intend to carry forward into preclinical testing.
Dr. David Wolf will be speaking on a panel presentation about AI in Healthcare and Spektron’s unique approach to medicinal molecule design. This invite-only presentation will be attended by investors looking to learn more about AI in this industry. Hosted by IMPACTIVE BioConsult, this presentation appends the 2019 BIO CEO SUMMIT and is being held 7:00 pm at Morgan Stanley.
Dr. David Wolf, the President and Chief Medical Officer for Spektron Systems, sat on the panel with other distinguished speakers talking about Artificial Intelligence. In this backstage interview clip, he about the revolutionary impact that AI is having in many industries. He addresses one of the key components of any good machine learning implementation – “Curation! Curation! Curation!”
We would like to give a big welcome to Iva for joining Spektron full time! Iva is one of our Computational Chemists and a great
Spektron Systems has actively engaged in developing synthesis and test plans on five representative molecules representing designs for an antipsychotic medication. Primarily for the purposes
We’re excited to be presenting our business to the Natural State Angel Association tonight! Bob D’Agostino and Tim Dockins have set up shop for the
Spektron System has submitted a Small Business Innovation Research Phase I grant proposal to the NSF for innovations in Computational Biology and Bioinformatics.
